Akebia Therapeutics Obtains $1,500,000 New Financing Round

  • Feed Type
  • Date
    7/3/2014
  • Company Name
    Akebia Therapeutics
  • Mailing Address
    245 First Street Cambridge, MA 02142 USA
  • Company Description
    Akebia Therapeutics (NASDAQ: AKBA) is a pharmaceutical company with a focus on treatments for ischemia and improvement of vascular disease.
  • Website
    http://www.akebia.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,500,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The company intends to use the capital to fund clinical development of HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD.
  • M&A Terms
  • Venture Investor
  • Venture Investor

By posting a comment, you agree to our terms and conditions.